Sun Pharma Japanese arm unveils Ilumya to treat plaque psoriasis
Psoriasis is a chronic immune disease that appears on the skin.
Mumbai: Drug major Sun Pharma on Wednesday said its Japanese subsidiary has launched its specialty product Ilumya, indicated for treatment of plaque psoriasis in adult patients in Japan.
In June this year, Sun Pharma said its subsidiary has got approval from the Japanese government for Ilumya.
In a regulatory filing, Sun Pharmaceutical Industries said its "wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection 100 mg Syringe in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies".
Junichi Nakamichi, Country Head, Sun Pharma Japan, said: "Ilumya is Sun Pharma's first innovative drug to be launched in the Japanese market".
Psoriasis is a chronic immune disease that appears on the skin.
Shares of Sun Pharma were trading 0.34 per cent higher at Rs 512.20 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.